Pediatric acute lymphoblastic leukemia: redefining outcomes.
Kadan-Lottick
Nina
N
Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, USA.
Neglia
Joseph P
JP
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001288:Attention / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003072:Cognition Disorders / Q000453:epidemiology / Q000209:etiology*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004333:Drug Administration Routes; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000009:adverse effects; D007223:Infant; D007859:Learning Disabilities / Q000453:epidemiology / Q000209:etiology; D008569:Memory Disorders / Q000453:epidemiology / Q000209:etiology; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009483:Neuropsychological Tests; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000523:psychology / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D017741:Survivors / Q000523:psychology*; D016896:Treatment Outcome
D003561:Cytarabine; D003907:Dexamethasone; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate